Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors

Virchows Archiv

Volumn 441, Issue 4, 2002, Pages 345-349

  Sulzbacher, Irene ^a   Birner, Peter ^a   Trieb, Klemens ^a   Lang, Susanna ^a   Chott, Andreas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Immunohistochemistry; Osteopontin; Osteosarcoma; VEGF

Indexed keywords

OSTEOPONTIN; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE CANCER; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; OSTEOBLAST; OSTEOBLASTOMA; OSTEOCLAST; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANK SUM TEST;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; BONE REMODELING; CELL COUNT; CHILD; DISEASE-FREE SURVIVAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MALE; MIDDLE AGED; OSTEOBLASTOMA; OSTEOPONTIN; OSTEOSARCOMA; SIALOGLYCOPROTEINS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036916990     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-002-0671-4     Document Type: Article

References (22)

1. Bellahcene A, Castronovo V (1995) Increased expression of osteonectin and osteopontin, two matrix proteins, in human breast cancer. Am J Pathol 146:95-100
2. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Peruzzi CA, Dvorak HF, Senger DR (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610-623
3. Coomber BL, Denton J, Sylvestre A, Kruth S (1998) Blood vessel density in canine osteosarcoma. Can J Vet Res 62:199-204
4. Denhardt DT, Noda M (1998) Osteopontin expression and function: Role in bone remodeling. J Cell Biochem Suppl 30-31:92-102
5. Devoll RE, Li W, Woods KV, Pinero GJ, Butler WT, Farach-Carson MC, Happonen RP (1999) Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J Oral Pathol Med 28:97-101
6. Dodds RA, Connor JR, James IE, Rykaczewski EL, Appelbaum E, Dul E, Gowen M (1995) Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: An in vitro and ex vivo study of remodeling bone. J Bone Miner Res 10:1666-1680
7. Gaumann A, Pertow P, Mentzel T, Mayer E, Dahm M, Otto M, Kirkpatrick CJ, Kriegsmann J (2001) Osteopontin expression in primary sarcomas of the pulmonary artery. Virchows Arch 439:668-674
8. Kaplan EL and Meier P (1985) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
9. Kaya M, Wada T, Akatsuka T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S (2000) Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6:572-577
10. Lee HY, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, Fukuda H, Nakano H, Abe S, Tateishi A, Kijima H, Yamazaki H, Tamaoki N, Ueyama Y, Nakamura M (1999) Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35:1089-1093
11. Merry K, Dodds R, Littlewood A, Gowen M (1993) Expression of osteopontin mRNA by osteoclasts and osteoblasts in modelling human bone. J Cell Sci 104:1013-1020
12. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, Tsuji K, Nifuji A, Denhardt DT, Noda M (2001) Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 16:652-659
13. Pockwinse SM, Wilming LG, Conlon DM, Stein GS, Lian JB (1992) Expression of cell growth and bone specific genes at single cell resolution during development of bone tissue-like organization in primary osteoblast cultures. J Cell Biochem 49:310-323
14. Rodan GA, Noda M (1991) Gene expression in osteoblastic cells. Crit Rev Eukaryot Gene Expr 1:85-98
15. Salzer-Kuntschik M, Brand G, Delling G (1983) Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe 4:135-141
16. Senger RS, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M (1996) Stimulation of endothlial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the αvβ3 integrin, osteopontin, and thrombin. Am J Pathol 149:293-305
17. Shijubo N, Uede T Kon S, Nagata M, Abe S (2000) Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 11:135-146
18. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605-611
19. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, Chambers AF (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121:578-584
20. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E (1998) Co- expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79:127-132
21. Weber GF, Ashkar S, Glimcher MJ, Cantor H (1996) Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271: 509-512
22. Winkler K, Bielack S, Delling G, Salzer-Kuntschik M, Kotz R, Greenshaw C, Jurgens H, Ritter J, Kusnierz-Glaz C, Errtmann R, et al (1990) Effect of intraarteriel versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (COSS-86). Cancer 66:1703-1710